Enoxaparin (Monograph)

Drug class: Heparins
- Low molecular weight Heparins
- LMWHs
CAS number: 9005-49-6

Medically reviewed by Drugs.com on Sep 25, 2023. Written by ASHP.

Warning

Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWHs) or heparinoids and are receiving neuraxial (spinal/epidural) anesthesia or spinal puncture; may result in long-term or permanent paralysis.¹ ²⁶ ¹⁴² (See Spinal/Epidural Hematomas under Cautions.)
Risk increased by use of indwelling epidural catheters or by concomitant use of drugs affecting hemostasis (e.g., NSAIAs, platelet-aggregation inhibitors, other anticoagulants).¹ ²⁶ ¹⁴² ¹⁴³
Risk also increased by history of traumatic or repeated epidural or spinal puncture, spinal deformity, or spinal surgery.¹ ²⁶
Optimal timing between administration of enoxaparin and neuraxial procedures not known.¹
Monitor frequently for signs and symptoms of neurologic impairment and treat urgently if neurologic compromise noted.¹ ²⁶ ¹⁴² ¹⁴³

Introduction

Anticoagulant; LMWH.¹ ² ³ ⁴

Uses for Enoxaparin

Thromboprophylaxis in General/Abdominal Surgery

Prevention of venous thromboembolism (VTE; DVT and/or PE) in patients undergoing general/abdominal surgery who are at risk for thromboembolic complications.¹ ²⁷ ⁶⁶ ⁷¹

Decisions regarding use of thromboprophylaxis in patients undergoing general surgery should be based on patient’s level of risk for thromboembolism and bleeding.¹⁰⁰² ¹¹⁰¹

Pharmacologic prophylaxis (with LMWHs or low-dose unfractionated heparin) generally recommended in patients with moderate to high risk of VTE who do not have a high risk of bleeding.¹⁰⁰² ¹¹⁰¹ ¹¹⁰³

Extended VTE prophylaxis may be considered in selected patients undergoing major surgery.¹⁰⁰² ¹¹⁰¹ Because risk of VTE is particularly high in patients undergoing abdominal or pelvic surgery for cancer, extended (up to 4 weeks) prophylaxis with LMWHs is recommended in such patients.¹⁰⁰² ¹¹⁰³

The American College of Chest Physicians (ACCP) states that recommendations for use of antithrombotic agents in general surgery patients can be applied to patients undergoing bariatric, vascular, and plastic/reconstructive surgery.¹⁰⁰²

Thromboprophylaxis in Hip-Replacement, Knee-Replacement, or Hip-Fracture Surgery

Prevention of postoperative DVT, which may lead to PE, in patients undergoing hip-replacement surgery.¹ ² ³ ⁵ ⁶ ⁷ ²⁰ ²¹ ²² ²⁷ ³⁴ ³⁵ ³⁶ ³⁷ ³⁸ ¹⁰⁰³ ¹¹⁰¹

Prevention of DVT and/or PE in patients undergoing knee-replacement surgery.¹ ²⁰ ²² ¹⁰⁰³ ¹¹⁰¹

Also has been used for thromboprophylaxis in patients undergoing hip-fracture surgery^{† [off-label]}.¹⁰⁰³ ¹¹⁰¹

ACCP recommends routine thromboprophylaxis (with a pharmacologic and/or mechanical method) in all patients undergoing major orthopedic surgery because of high risk of postoperative VTE; continue thromboprophylaxis for at least 10–14 days.¹⁰⁰³

Among the various antithrombotic agents (e.g., LMWHs, fondaparinux, direct oral anticoagulants [DOACs], low-dose unfractionated heparin, warfarin, aspirin), ACCP states that LMWHs are generally preferred because of relative efficacy and safety and extensive clinical experience; alternative agents may be considered if LMWHs are not available or cannot be used (e.g., patients with heparin-induced thrombocytopenia [HIT] or those who refuse or are uncooperative with sub-Q injections).¹⁰⁰³

More recent guidelines from the American Society of Hematology (ASH) suggest aspirin or an anticoagulant for VTE prophylaxis in patients undergoing total hip or total knee arthroplasty.¹¹⁰¹ If an anticoagulant is used, DOACs are suggested over LMWHs; if DOACs are not used, LMWHs are generally preferred to warfarin or unfractionated heparin.¹¹⁰¹ For patients undergoing hip fracture repair, ASH suggests either LMWHs or unfractionated heparin.¹¹⁰¹

When selecting an appropriate thromboprophylaxis regimen, consider factors such as relative efficacy and bleeding risk as well as other logistics and compliance issues.¹⁰⁰³

Because risk of DVT is increased for several months following hip- or knee-replacement surgery,³⁵ ³⁶ ³⁸ ACCP suggests extended prophylaxis for up to 35 days in patients undergoing major orthopedic surgery; ASH states that extended VTE prophylaxis (generally considered as >3 weeks) may be considered in selected patients undergoing major surgery.¹⁰⁰³ ¹¹⁰¹

Thromboprophylaxis in Other Surgical Settings

Also has been used for VTE prophylaxis in patients undergoing other types of surgery including neurosurgery^{† [off-label]}, cardiac surgery^{† [off-label]}, and vascular surgery^{† [off-label]}.¹⁰⁰² ¹¹⁰¹

Thromboprophylaxis in Acutely Ill Medical Patients

Prevention of DVT, which may lead to PE, in patients who are at increased risk of thromboembolic complications due to severely restricted mobility during acute illness.¹ ⁶⁷ ⁷¹ ¹⁰⁰¹

Treatment decisions regarding use of VTE prophylaxis in acutely ill hospitalized patients should include assessment of the patient's risk of thromboembolism and risk of bleeding.¹⁰⁰¹ ¹¹⁰⁸

LMWHs are recommended as one of several options for thromboprophylaxis in acutely ill, hospitalized medical patients (including those in the ICU).¹⁰⁰¹ ¹¹⁰⁸

ACCP suggests continued thromboprophylaxis for 6–21 days until full mobility is restored or hospital discharge, whichever comes first.¹⁰⁰¹ Extended thromboprophylaxis after hospital discharge may be considered in selected patients.¹¹⁰⁸ ¹¹⁰⁹

Risk of VTE is particularly high in patients with cancer.¹⁰⁰¹ ¹¹⁰² ¹¹⁰³ In acutely ill hospitalized patients with cancer, thromboprophylaxis is generally recommended, with LMWHs suggested over unfractionated heparin.¹¹⁰³ Routine thromboprophylaxis generally not recommended in cancer patients in the outpatient setting who have no additional risk factors for VTE.¹¹⁰² ¹¹⁰³

Thromboprophylaxis in Trauma Patients

LMWHs also have been used for VTE prophylaxis in trauma patients^{† [off-label]}.¹⁰⁰² ¹¹⁰¹

Treatment and Secondary Prevention of VTE

Inpatient treatment of acute DVT with or without PE when administered in conjunction with warfarin.¹ ²⁸ ¹⁰⁰⁵

Outpatient treatment of acute DVT without PE when administered in conjunction with warfarin.¹ ²⁸ ¹⁰⁰⁵

Although labeled indication includes the use of warfarin in conjunction with enoxaparin for treatment of VTE, other anticoagulants other than warfarin (e.g., direct oral anticoagulants [DOACs]) have been used for long-term anticoagulation following initial treatment with enoxaparin.¹¹⁰⁴

LMWHs are recommended as one of several parenteral anticoagulant options for initial treatment of acute VTE; however, initial treatment with a parenteral anticoagulant may not always be necessary since oral anticoagulant options are available.¹⁰⁰⁵ ¹¹⁰² ¹¹⁰³ ¹¹⁰⁴

Continue anticoagulant therapy for at least 3 months, and possibly longer depending on individual clinical situation.¹⁰⁰⁵ ¹¹⁰⁴ In patients with cancer, anticoagulation therapy is recommended for at least 6 months; treatment beyond 6 months may be considered in selected patients.¹¹⁰² For long-term anticoagulant therapy (secondary prevention), ACCP states DOACs are generally preferred in patients without cancer; in patients with cancer, LMWHs or DOACs are generally suggested over warfarin for long-term anticoagulation.¹¹⁰² ¹¹⁰³ ¹¹⁰⁴

LMWHs also have been used for treatment and secondary prevention of VTE in pediatric patients^†.¹⁰¹³ Unlike adults, most episodes of VTE in children are secondary to an identifiable risk factor such as a central venous access device.¹⁰¹³

Non-ST-Segment-Elevation Acute Coronary Syndromes (NSTE-ACS)

Used in conjunction with aspirin to reduce risk of ischemic complications (death, MI) in patients with NSTE-ACS (unstable angina or non-ST-segment-elevation MI [NSTEMI]).¹ ⁴⁰ ⁴¹ ⁴² ⁴³ ⁴⁸ ⁵³ ¹⁴⁶ ⁹⁹¹

Initial parenteral anticoagulants with established efficacy in patients with NSTE-ACS include enoxaparin, unfractionated heparin, bivalirudin (only in patients managed with an early invasive strategy), and fondaparinux.⁹⁹¹

In patients undergoing PCI, an additional IV dose of enoxaparin may be required based on timing of the last administered sub-Q dose.⁹⁹⁴

ST-Segment-Elevation MI (STEMI)

Used in conjunction with aspirin for treatment of acute STEMI in patients managed medically (with thrombolytic therapy) or with subsequent PCI.¹ ¹⁶² ¹⁶⁴ ¹⁶⁵ ⁵²⁷ ⁹⁹⁴

ACCF and AHA state that patients with STEMI undergoing thrombolytic therapy should receive an anticoagulant (e.g., unfractionated heparin, enoxaparin, fondaparinux) for ≥48 hours, and preferably for the duration of the index hospitalization, up to 8 days or until revascularization is performed.⁵²⁷ Enoxaparin is preferred over unfractionated heparin if extended anticoagulation (>48 hours) is necessary.⁵²⁷

Adjunctive use of LMWHs in patients with acute STEMI associated with improvement in short-term clinical outcomes (e.g., death, reinfarction, recurrent ischemia) with generally similar rates of bleeding complications compared with unfractionated heparin or placebo.¹²⁹ ¹³⁰ ¹³¹ ¹³² ¹³³

In patients undergoing PCI, an additional IV dose of enoxaparin may be required based on the timing of the last administered sub-Q dose.¹ ⁹⁹⁴

Thromboprophylaxis in Acute Ischemic Stroke

LMWHs have been used for thromboprophylaxis in selected patients with acute ischemic stroke^†; those with additional risk factors for VTE are more likely to benefit from such prophylaxis.¹⁰⁰⁹

LMWHs also have been used for initial management of acute arterial ischemic stroke in children^† until dissection and embolic causes have been excluded.¹⁰¹³

Thromboembolism During Pregnancy

Prevention and treatment of VTE during pregnancy^†.¹⁰¹² ¹¹⁰⁴ LMWHs are recommended by ACCP for this use; there is a potential for other agents to cross the placenta.¹⁰¹² ¹¹⁰⁴ ACCP recommends LMWHs for initial treatment and secondary prevention throughout the remainder of the pregnancy.¹⁰¹² To prevent recurrence, anticoagulation should be continued for ≥6 weeks and for a total duration of ≥3 months.¹⁰¹²

Prevention of thrombotic complications in pregnant women with mechanical heart valves^†.¹³⁸ ⁹⁹⁶ However, cases of valve thrombosis resulting in death (including maternal and fetal deaths) and/or requiring surgical intervention reported with such use.¹ ⁶⁸ ⁶⁹ ⁷⁰ ⁷¹ ⁸³ ⁹⁷ ⁹⁸ ⁹⁹⁶ (See Patients with Mechanical Prosthetic Heart Valves under Cautions.)

Also has been used in combination with low-dose aspirin for prevention of recurrent pregnancy loss in women with antiphospholipid antibody (APLA) syndrome^†.¹⁰¹²

In general, thromboprophylaxis (e.g., with an LMWH) is suggested during the antepartum period only in pregnant women who have a history of thromboembolism^† and are considered to be at moderate to high risk of recurrent events (e.g., those with a single episode of unprovoked VTE, pregnancy- or estrogen-related venous thromboembolism, history of multiple unprovoked events).¹⁰¹²

Hereditary thrombophilias and a family history of VTE substantially increase risk of pregnancy-related VTE.¹⁰¹² ACCP suggests antepartum and postpartum prophylaxis with an LMWH in some pregnant women with high-risk hereditary thrombophilias (e.g., homozygous genetic mutations for factor V Leiden or prothrombin G20210A)^†.¹⁰¹²

Discontinue LMWH therapy ≥24 hours prior to induction of labor or cesarean section (or expected time of neuraxial anesthesia) to avoid an unwanted anticoagulant effect on fetus.⁹⁹⁶ ¹⁰¹²

Cardioversion of Atrial Fibrillation/Flutter

LMWHs have been used for prevention of stroke and systemic embolism in patients with atrial fibrillation or atrial flutter undergoing electrical or pharmacologic cardioversion^†.⁹⁹⁹ ¹⁰⁰⁷ ¹¹⁰⁵

Therapeutic anticoagulation with LMWHs has been used at the time of transesophageal echocardiography (TEE) in patients with atrial fibrillation lasting ≥48 hours or of unknown duration, followed by cardioversion within 24 hours if no thrombus is detected.⁹⁹⁹ ¹⁰⁰⁷ ¹¹⁰⁵

Patients with atrial fibrillation of <48 hours' duration and a high risk of stroke (CHA₂DS₂-VASc score ≥2 for males or ≥3 for females) usually do not require prolonged anticoagulation or TEE prior to cardioversion; LMWHs (in therapeutic dosages) may be used at presentation, followed by immediate cardioversion and long-term anticoagulation in these patients.⁹⁹⁹ ¹⁰⁰⁷ ¹¹⁰⁵

In patients with atrial fibrillation of <48 hours' duration and a low risk of stroke (CHA₂DS₂-VASc score of 0 for males or 1 for females), either therapeutic anticoagulation or no anticoagulation may be considered prior to cardioversion.⁹⁹⁹ ¹¹⁰⁵

After successful cardioversion in patients with atrial fibrillation of ≥48 hours' duration, therapeutic anticoagulation is recommended for ≥4 weeks.⁹⁹⁹ ¹⁰⁰⁷ Patients with atrial fibrillation of <48 hours' duration who have a low risk of stroke generally do not require anticoagulation postcardioversion.⁹⁹⁹ ¹¹⁰⁵ In all situations, the decision to administer long-term anticoagulation following cardioversion should be based on the patient's risk of thromboembolism and risk of bleeding.⁹⁹⁹ ¹¹⁰⁵

Thromboprophylaxis in Patients with Prosthetic Heart Valves

Has been used to reduce risk of thromboembolism during conversion to maintenance oral anticoagulant therapy (e.g., warfarin) in patients with prosthetic mechanical heart valves^†.⁶⁴ ⁸³ ⁸⁷ ⁹⁰ ⁹³ ⁹⁷ ⁹⁸ ¹⁰⁰⁸ (See Patients with Mechanical Prosthetic Heart Valves under Cautions.)

In patients with a mechanical heart valve in whom therapy with an oral anticoagulant must be temporarily discontinued (e.g., those undergoing major surgery), bridging anticoagulation^† with an LMWH has been used in selected patients (e.g., those at high risk for thromboembolism).⁹⁹⁶ ¹⁰⁰⁴

Has been used for thromboprophylaxis in pregnant women with prosthetic mechanical heart valves^†.¹³⁸ ⁹⁹⁶ ¹⁰¹² (See Thromboembolism During Pregnancy under Uses.)

Bridging Anticoagulation

Has been used for bridging anticoagulation^† during temporary interruption of long-term oral anticoagulant therapy in selected patients with VTE, atrial fibrillation, or mechanical prosthetic heart valves undergoing surgery or other invasive procedures; use and type of bridging anticoagulation depend on patient's risk of developing thromboembolism without anticoagulant therapy.¹⁰⁰⁴

Bridging anticoagulation has been associated with increased risk of major bleeding without a significant effect on arterial thromboembolism in some settings and therefore should be considered on an individual basis.⁹⁹⁶ ¹⁰¹⁴

Enoxaparin Dosage and Administration

General

Patient Monitoring

Since coagulation parameters such as PT or aPTT are insensitive for monitoring enoxaparin activity, routine monitoring of coagulation parameters generally not required.¹
Monitoring of anti-factor Xa levels may be helpful in high-risk groups, such as pregnant patients, patients with renal impairment, patients at extremes of weight, or if abnormal coagulation parameters or bleeding occurs during treatment.¹ ¹²⁸ ¹³⁵
If LMWHs are used for anticoagulation in children, the American College of Chest Physicians (ACCP) suggests that dosage be adjusted to a target anti-factor Xa level of 0.5–1 units/mL based on a sample taken 4–6 hours, or 0.5–0.8 units/mL based on a sample taken 2–6 hours, following sub-Q administration.¹⁰¹³
In patients with NSTE-ACS, adhere precisely to intervals recommended between doses to minimize the risk of bleeding.¹ If a closure device is used, may remove sheath immediately after PCI.¹ Otherwise, if a manual compression method is used, remove vascular access sheath 6 hours following the last dose of enoxaparin sodium.¹ If continuing enoxaparin therapy, administer the next scheduled dose no sooner than 6–8 hours after sheath removal.¹ Observe procedure site for signs of bleeding or hematoma formation.¹

Administration

Administer by deep sub-Q injection for most indications; do not give IM.¹

Single doses also administered by direct IV injection in certain situations.¹ (See STEMI and also see NSTE-ACS under Dosage and Administration.)

When using multiple-dose vials, withdraw dose using a tuberculin or equivalent syringe.¹

Do not mix with other injections or infusions.¹

IV Administration

May be administered by direct IV injection.¹ Use multiple-dose vial for IV administration.¹

To avoid mixing IV enoxaparin with other drugs, flush IV line with a sufficient amount of 0.9% sodium chloride injection or 5% dextrose injection prior to and following IV administration of enoxaparin.¹

Sub-Q Administration

Administer with patient in the supine position.¹

To avoid loss of drug when using the prefilled syringes, do not expel air from syringe prior to injection.¹

For prescribed doses less than a full syringe volume, eject excess volume until only the prescribed dose remains.¹

Inject drug sub-Q into the left and right anterolateral and left and right posterolateral abdominal wall.¹

Insert the entire length of the needle into a skin fold created by the thumb and forefinger; hold the skin fold until the needle is withdrawn.¹

Alternate injection sites frequently.¹

To minimize bruising, do not massage injection sites after injection.¹

Dosage

Available as enoxaparin sodium; dosage expressed in terms of the salt.¹

Dosages for enoxaparin sodium or other LMWHs and heparin cannot be used interchangeably on a unit-for-unit (or mg-for-mg) basis.¹

Available as enoxaparin sodium.¹ Enoxaparin sodium has an approximate anti-factor Xa activity of 100 units/mg using the WHO First International Low Molecular Weight Heparin Reference Standard.¹

Adults

Prevention of VTE

General/Abdominal Surgery

Sub-Q

40 mg once daily initiated 2 hours prior to surgery.¹

Usual duration of therapy is 7–10 days, although up to 12 days of treatment has been well tolerated in clinical trials.¹ ⁷¹

Extended VTE prophylaxis (generally considered as >3 weeks) may be considered in selected patients undergoing major general surgery.¹¹⁰¹ Extended prophylaxis (for up to 4 weeks) recommended by ACCP in patients undergoing abdominal or pelvic surgery for cancer.¹⁰⁰²

Hip-Replacement Surgery

Sub-Q

30 mg every 12 hours initiated 12–24 hours after surgery, provided hemostasis has been established.¹

Alternatively, may consider dosage of 40 mg once daily, initiated approximately 12 hours before surgery.¹

Because of risk of bleeding, ACCP recommends that LMWHs be initiated at least 12 hours preoperatively or at least 12 hours postoperatively in patients undergoing major orthopedic surgery.¹⁰⁰³

Continue prophylaxis throughout the postoperative period, generally for 7–10 days, until risk of DVT has diminished; manufacturer states that up to 14 days of thromboprophylaxis was well tolerated in clinical trials.¹

Following the initial phase of thromboprophylaxis during the acute postoperative period, manufacturer recommends continued prophylaxis with 40 mg once daily for 3 weeks.¹⁵⁰

ACCP recommends a minimum of 10–14 days of thromboprophylaxis, and suggests extending prophylaxis for up to 35 days on an outpatient basis.¹⁰⁰³ ASH guidelines state that extended VTE prophylaxis (generally considered as >3 weeks) may be considered in selected patients undergoing major surgery.¹¹⁰¹

Knee-Replacement Surgery

Sub-Q

30 mg every 12 hours initiated 12–24 hours after surgery, provided hemostasis has been established.¹

Because of risk of bleeding, ACCP recommends that LMWHs be initiated at least 12 hours preoperatively or 12 hours postoperatively in patients undergoing major orthopedic surgery.¹⁰⁰³

Acutely Ill Medical Patients

Sub-Q

40 mg once daily.¹ Usual duration of therapy is 6–11 days; well tolerated for up to 14 days in clinical trials.¹

ACCP suggests against the use of extended thromboprophylaxis beyond the period of patient immobilization or acute hospital stay in acutely ill medical patients.¹⁰⁰¹ However, extended thromboprophylaxis has been used in selected patients after hospital discharge.¹¹⁰⁸ ¹¹⁰⁹

Treatment of VTE

Sub-Q

Outpatient treatment in patients with uncomplicated DVT without PE: 1 mg/kg every 12 hours.¹ ²⁹

Inpatient (hospital) treatment in patients with DVT with or without PE: 1 mg/kg every 12 hours or 1.5 mg/kg once daily at the same time every day.¹

Manufacturer states average duration of therapy is 7 days.¹ In patients with VTE, ACCP recommends that anticoagulant therapy be continued beyond the acute treatment period for at least 3 months, and possibly longer depending on whether the VTE event was unprovoked or provoked (by a transient risk factor (e.g., surgery), presence of cancer, and patient's risk of bleeding.¹⁰⁰⁵ ¹¹⁰⁴

Transitioning from Enoxaparin to Oral Anticoagulants

Patients transitioning to warfarin for long-term anticoagulant therapy: initiate warfarin when appropriate (usually within 72 hours of enoxaparin initiation) and continue for a minimum of 5 days and until a therapeutic INR (2–3) has been achieved.¹ Discontinue enoxaparin after this period of overlap with warfarin,²⁹ generally after 7 days of enoxaparin treatment.¹

Patients transitioning to dabigatran for long-term anticoagulant therapy: Administer enoxaparin for 5–10 days.¹⁶⁸ Discontinue enoxaparin and initiate dabigatran 0–2 hours prior to the time of next scheduled dose of enoxaparin.¹⁶⁸

Patients transitioning to edoxaban for long-term anticoagulant therapy: Administer enoxaparin for 5–10 days.¹⁶⁹ Discontinue enoxaparin and initiate edoxaban at the time of the next scheduled dose of enoxaparin.¹⁶⁹

Patients transitioning to apixaban for long-term anticoagulant therapy: Discontinue enoxaparin and initiate apixaban at the time of the next scheduled dose of enoxaparin.¹⁷⁰

Patients transitioning to rivaroxaban for long-term anticoagulant therapy: Discontinue enoxaparin and initiate rivaroxaban 0–2 hours prior to the time of the next scheduled dose of enoxaparin.¹⁷¹

NSTE-ACS

Sub-Q

1 mg/kg every 12 hours in conjunction with aspirin therapy (100–325 mg once daily).¹

Initiate as soon as possible after hospital admission.⁹⁹¹ Administer for a minimum of 2 days and continue until clinical stabilization.¹ ⁴¹ ⁴²

Usual duration of treatment is 2–8 days, although up to 12.5 days of treatment has been well tolerated in clinical trials.¹ ⁴¹ ⁴²

Patients undergoing PCI who have not received prior anticoagulant therapy: ACCF/AHA/SCAI state that it is reasonable to administer enoxaparin sodium (e.g., 0.5–0.75 mg/kg by direct IV injection) at the time of PCI^†.⁹⁹⁴

Patients in whom sub-Q enoxaparin has been initiated prior to PCI (“upstream”): ACCF/AHA/SCAI state that an additional 0.3-mg/kg dose of enoxaparin sodium should be given by direct IV injection at the time of PCI if fewer than 2 prior therapeutic (e.g., 1 mg/kg) sub-Q doses of enoxaparin sodium have been given or if the last sub-Q dose of the drug was administered 8–12 hours before PCI^†.⁹⁹⁴

To minimize the possibility of bleeding associated with vascular (e.g., vascular access sheath) instrumentation (e.g., PCI), adhere strictly to dosage intervals and observe precautions in removing vascular access sheath.¹ Administer next dose of enoxaparin sodium no sooner than 6–8 hours after removal of vascular access sheath;¹ ACCF/AHA/SCAI suggest removal of femoral sheath when ACT falls to <150–180 seconds or aPTT falls to <50 seconds.⁹⁹⁴ Monitor vascular access sites carefully for signs of bleeding or hematoma formation after removal of vascular sheath and during enoxaparin treatment.¹

STEMI

IV, then Sub-Q

Patients <75 years of age: 30 mg by direct IV injection. Follow with 1 mg/kg sub-Q every 12 hours (maximum 100 mg per dose for each of the first 2 sub-Q doses, then 1 mg/kg per dose thereafter);¹ give first sub-Q dose immediately after direct IV dose.¹

Patients ≥75 years of age: 0.75 mg/kg sub-Q every 12 hours (maximum dose 75 mg for each of the first 2 doses only, then 0.75 mg/kg per dose thereafter); do not administer an initial IV dose.¹

When used with thrombolytic therapy, initiate enoxaparin therapy 15 minutes before to 30 minutes after initiation of thrombolytic therapy.¹

Manufacturer states optimal duration not known but likely >8 days; enoxaparin therapy was continued for 8 days or until hospital discharge in clinical trials.¹

Use in conjunction with aspirin therapy (75–325 mg once daily) unless contraindicated.¹

Patients undergoing PCI: If last sub-Q dose of enoxaparin sodium was administered ≥8 hours before PCI, manufacturer recommends an additional 0.3-mg/kg dose by direct IV injection during PCI.¹ ¹⁶⁶ ¹⁶⁷

To minimize possibility of bleeding associated with vascular (e.g., vascular access sheath) instrumentation (e.g., PCI), adhere strictly to dosage intervals and observe precautions in removing vascular access sheath.¹ Administer next dose of enoxaparin sodium no sooner than 6–8 hours after removal of vascular access sheath.¹ ACCF/AHA/SCAI suggest removal of femoral sheath after PCI when ACT falls to <150–180 seconds or aPTT falls to <50 seconds.⁹⁹⁴ Monitor vascular access sites carefully for signs of bleeding or hematoma formation after removal of vascular sheath and during enoxaparin treatment.¹

Treatment and Prevention of Thromboembolism During Pregnancy†

Sub-Q

Treatment of acute VTE: 1 mg/kg every 12 hours for the remainder of pregnancy; continue anticoagulation for ≥6 weeks postpartum (minimum total duration of 3 months).¹⁰¹²

Postpartum prophylaxis in pregnant women with prior VTE: Prophylactic (40 mg once daily) or intermediate (40 mg every 12 hours) dosage suggested.¹⁰¹²

Pregnant women receiving long-term warfarin therapy: If the decision is made to switch to an LMWH-based strategy, dose-adjusted LMWH is recommended; the LMWH may be administered throughout all 3 trimesters or, alternatively, administered during the first trimester, followed by warfarin during the second and third trimesters.⁹⁹⁶ Administer the LMWH at least 2 times daily with close monitoring of anti-factor Xa levels.⁹⁹⁶

Primary prevention of VTE in pregnant women with high-risk thrombophilias: Prophylactic (40 mg once daily) or intermediate (40 mg every 12 hours) dosage suggested.¹⁰¹²

Pregnant women with mechanical heart valves: If an LMWH is used, twice-daily administration recommended because of altered pharmacokinetics in pregnant women, with adjustment of enoxaparin sodium dosage to maintain anti-factor Xa levels of 0.8–1.2 units/mL 4 hours after dosing.⁹⁹⁶ Resume usual long-term anticoagulation postpartum.¹⁰¹² (See Patients with Mechanical Heart Valves under Cautions.)

Consider use of a shorter-acting anticoagulant as delivery approaches.¹ To avoid an unwanted anticoagulant effect on the fetus during delivery, discontinue LMWH ≥24 hours prior (or ≥12 hours prior if using prophylactic-dose LMWH) to induction of labor or cesarean section.¹⁰¹² Pregnant women with mechanical heart valves who are on LMWH should switch to unfractionated heparin ≥36 hours prior to planned delivery.⁹⁹⁶

Cardioversion of Atrial Fibrillation/Flutter†

Sub-Q

For prevention of stroke and systemic embolism in patients undergoing cardioversion for atrial fibrillation or atrial flutter^†, use of full VTE treatment dosages recommended.¹⁰⁰⁷

Bridging Anticoagulation†

Sub-Q

In patients receiving bridging anticoagulation during temporary interruption of oral anticoagulant therapy for surgery or other invasive procedures, ACCP suggests administering last preoperative dose of enoxaparin approximately 24 hours prior to surgery.¹⁰⁰⁴

Administer postoperative anticoagulation with caution and only when hemostasis achieved because of the potential for bleeding at surgical site.¹⁰⁰⁴ In patients undergoing procedures associated with high risk of bleeding, ACCP suggests delaying the resumption of therapeutic-dose enoxaparin until 48–72 hours after surgery when adequate hemostasis achieved.¹⁰⁰⁴

Special Populations

Hepatic Impairment

No special population dosage recommendations at this time.¹

Renal Impairment

Use with caution in renally impaired patients.¹ ³ ¹²⁸ No dosage adjustments necessary in patients with mild (Cl_cr 50–80 mL/minute) or moderate (Cl_cr 30–50 mL/minute) renal impairment.¹

Adjust dosage for patients with severe renal impairment (Cl_cr <30 mL/minute).¹ ¹⁰⁰⁰ (See Table 1.)

Table 1: Dosage Recommendations for Patients with Severe Renal Impairment (Clcr <30 mL/minute)1
Indication	Dosage Regimen
VTE prophylaxis in abdominal surgery	30 mg administered sub-Q once daily
VTE prophylaxis in hip- or knee-replacement surgery	30 mg administered sub-Q once daily
VTE prophylaxis in medical patients during acute illness	30 mg administered sub-Q once daily
Treatment of acute VTE in hospitalized patients (when administered in conjunction with warfarin)	1 mg/kg administered sub-Q once daily
Outpatient treatment of acute VTE (when administered in conjunction with warfarin)	1 mg/kg administered sub-Q once daily
Prophylaxis of ischemic complications of NSTE-ACS (when administered concurrently with aspirin)	1 mg/kg administered sub-Q once daily
Treatment of acute STEMI in patients <75 years of age (when administered in conjunction with aspirin)	30 mg as a single direct IV injection plus a 1-mg/kg sub-Q dose; follow with sub-Q injections of 1 mg/kg once daily (maximum of 100 mg per dose for each of the first 2 sub-Q doses)¹ ⁷¹
Treatment of acute STEMI in patients ≥75 years of age (when administered in conjunction with aspirin)	1 mg/kg administered sub-Q once daily (maximum of 75 mg per dose for each of the first 2 doses)⁷¹ ; do not administer an initial IV dose

Geriatric Patients

Use with caution; careful attention to dosing intervals and concomitant medications (particularly antiplatelet drugs) advised.¹

Manufacturer states that no dosage adjustment necessary in geriatric patients for uses other than STEMI unless renal function is impaired.¹ (See Renal Impairment under Dosage and Administration.)

Low-Weight Patients

Carefully monitor for signs and symptoms of bleeding in patients with low body weight (women <45 kg or men <57 kg).¹ ⁷¹

Obese Patients

Safety and efficacy of thromboprophylactic doses in patients with body mass index (BMI) >30 kg/m² not established; closely monitor for signs and symptoms of thromboembolism in such patients.¹ ASH suggests using actual body weight for dosing in patients with acute VTE and not monitoring anti-factor Xa concentrations to guide dosage.¹¹⁰⁶

Cautions for Enoxaparin

Contraindications

Active major bleeding.¹
Immune-mediated heparin-induced thrombocytopenia within prior 100 days or associated with circulating antiplatelet antibodies.¹
Known hypersensitivity to enoxaparin sodium (e.g., pruritus, urticaria, anaphylactic/anaphylactoid reactions), heparin, pork products, benzyl alcohol, or any ingredient in the formulation.¹

Warnings/Precautions

Spinal/Epidural Hematomas

Epidural or spinal hematoma reported with concurrent use of anticoagulants (e.g., LMWHs, heparinoids) and neuraxial (spinal/epidural) anesthesia or spinal puncture procedures.¹ ¹⁶¹ ¹⁶³ Such hematomas have resulted in neurologic injury, including long-term or permanent paralysis.¹ ¹⁶¹ (See Boxed Warning.)

Prior to performing a spinal or epidural procedure, determine whether a patient is receiving anticoagulants.¹⁶¹

Carefully consider the timing of spinal catheter placement and removal in relation to anticoagulant use, considering both dosage and pharmacokinetic properties (e.g., elimination half-life) of the anticoagulant.¹ ¹⁶¹

Insertion or removal of catheter is best performed when the anticoagulant effect of enoxaparin is minimal (e.g., ≥12 hours after a low dose [30 mg once or twice daily or 40 mg once daily] or ≥24 hours after a high dose [0.75 mg/kg twice daily, 1 mg/kg twice daily, or 1.5 mg/kg once daily]).¹ ¹⁶¹ In patients receiving a twice-daily treatment dosage (0.75 or 1 mg/kg twice daily), omit second dose to allow for a longer delay between doses.¹ Consider doubling these recommended time delays in patients with renal impairment.¹

Consider delaying subsequent dose of enoxaparin for ≥4 hours after catheter removal based on patient's risk of bleeding versus thrombosis.¹ ¹⁶¹

Frequently monitor for signs of neurologic impairment (e.g., midline back pain, numbness or weakness in lower limbs, bowel or bladder dysfunction).¹ If spinal hematoma suspected, diagnose and treat immediately; consider spinal cord decompression even though it may not prevent or reverse neurologic sequelae.¹

Bleeding

Risk of serious, potentially fatal bleeding.¹ Search for bleeding site if an unexplained decrease in hematocrit or BP occurs.¹

Use with extreme caution in patients with increased risk of hemorrhage.¹ Such patients include those with bacterial endocarditis; congenital or acquired bleeding disorders; active ulceration and angiodysplastic GI disease; hemorrhagic stroke; or recent brain, spinal, or ophthalmologic surgery.¹

Increased risk for hemorrhage in patients treated concomitantly with platelet inhibitors.¹

Use with caution in patients with bleeding diathesis, uncontrolled arterial hypertension, or a history of recent GI ulceration, diabetic retinopathy, renal dysfunction, or hemorrhage.¹

Periodic CBCs, including platelet counts, and stool occult blood tests recommended.¹ If abnormal coagulation parameters or bleeding occurs, may consider use of anti-factor Xa levels to monitor anticoagulant effects of enoxaparin.¹

Carefully monitor patients with low body weight or renal impairment for signs and symptoms of bleeding.¹

Protamine sulfate may be used to neutralize the anticoagulant effect of enoxaparin if bleeding occurs.¹ Because fatal reactions resembling anaphylaxis have been reported with protamine sulfate administration, use only when resuscitation techniques and treatment for anaphylactic shock are readily available.¹

To minimize risk of bleeding during percutaneous revascularization procedures, adhere precisely to recommended dosing intervals.¹ Ensure hemostasis at puncture site after PCI; observe for signs of bleeding or hematoma formation.¹ If arterial closure device used, may remove sheath immediately; if manual compression used, remove sheath 6 hours after last dose of enoxaparin.¹ Administer next scheduled dose no sooner than 6–8 hours after sheath removal.¹

Thrombocytopenia

Cases of HIT and HITTS reported, including complications such as organ infarction, limb ischemia, or death.¹ Use with extreme caution in patients with history of HIT/HITTS; use only if ≥100 days since prior episode and absence of circulating antiplatelet antibodies.¹ Monitor thrombocytopenia of any degree closely.¹ If platelet count <100,000/mm³, discontinue enoxaparin.¹ Consider use of nonheparin anticoagulants in patients with history of HIT/HITTS since recurrence possible.¹ (See Contraindications under Cautions.)

Interchangeability with Other Heparins

Do not use enoxaparin sodium interchangeably with other LMWHs or unfractionated heparin because of differences in manufacturing process, molecular weight distribution, anti-factor Xa and anti-factor II_a activities, dosage units, and dosage.¹ (See Dosage under Dosage and Administration.)

Patients with Mechanical Prosthetic Heart Valves

Valve thrombosis resulting in death and/or requiring surgical intervention reported during prophylaxis in some patients with mechanical prosthetic heart valves, including pregnant women.¹ ⁶⁸ ⁶⁹ ⁷⁰ ⁷¹ ⁸² ⁸³ ⁸⁵ ⁸⁷ ⁹⁰ Women with mechanical prosthetic heart valves are at higher risk for thromboembolism during pregnancy.¹ ⁸⁵ If enoxaparin is used in pregnant women with mechanical prosthetic heart valves, monitor peak and trough anti-factor Xa concentrations frequently and adjust dosage if necessary to maintain anti-factor Xa levels of 0.7–1.2 units/mL 4 hours after dosing.¹ ⁷¹ ⁸² ⁸³ ⁹³

Specific Populations

Pregnancy

Crosses placenta in animals, but not in humans.¹ ¹¹⁰⁷ No evidence of teratogenicity or fetotoxicity.¹ ACOG considers use of LMWHs generally safe in pregnancy.¹¹⁰⁷ Because benzyl alcohol may cross the placenta, enoxaparin in multiple-dose vials containing benzyl alcohol should be used with caution and only if clearly needed in pregnant women.¹

Maternal and neonatal hemorrhage reported; potentially fatal.¹

Use of enoxaparin for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves may result in valve thrombosis.¹ (See Patients with Mechanical Prosthetic Heart Valves under Cautions.) Frequent monitoring of peak and trough levels of anti-factor Xa required.¹

Monitor pregnant women carefully for evidence of bleeding or excessive anticoagulation.¹ As delivery approaches, consider use of a shorter-acting anticoagulant.¹ (See Boxed Warning.)

Lactation

Not known whether enoxaparin is distributed into breast milk; limited distribution into rat milk.¹ Not known whether enoxaparin affects breast-fed child or milk production.¹ ACOG considers use of LMWHs compatible with lactation.¹ ¹¹⁰⁷ ACCP recommends that LMWHs be continued in nursing women who are already receiving such therapy.¹⁰¹²

Pediatric Use

Manufacturer states safety and efficacy not established.¹

Large amounts of benzyl alcohol (i.e., 100–400 mg/kg daily) has been associated with toxicity (e.g., “gasping syndrome” and fatal reactions) in neonates;¹ ⁸⁰ ⁸¹ each mL of enoxaparin sodium injection in multiple-dose vials contains 15 mg of benzyl alcohol as a preservative.¹

Geriatric Use

Use with caution.¹ No substantial differences in efficacy relative to younger adults.¹ Possible increased risk of bleeding complications.¹ Pay careful attention to dosing intervals and concomitant medications (especially antiplatelet medications).¹ Consider monitoring (i.e., with anti-factor Xa assay) geriatric patients with low body weight (<45 kg) and those predisposed to decreased renal function.¹

Renal Impairment

Use with caution; carefully monitor for manifestations of bleeding.¹ Monitor anti-factor Xa concentrations in patients with appreciable renal impairment.¹ Hyperkalemia reported in patients with renal failure receiving enoxaparin.¹

Decreased clearance.¹ Dosage adjustments necessary in patients with severe renal impairment. ¹ ¹²⁸ (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Anemia, ecchymosis, thrombocytopenia, elevation of serum aminotransferase concentrations, fever, nausea, diarrhea, peripheral edema, dyspnea, injection site pain, confusion.¹

Drug Interactions

Drugs Affecting Hemostasis

Potential pharmacodynamic interaction with concomitant use of anticoagulants, platelet-aggregation inhibitors, or other drugs affecting hemostasis (increased risk of bleeding complications).¹ Use with caution.¹

Specific Drugs

Drug	Interaction	Comments
Anticoagulants	Increased risk of bleeding¹ No pharmacokinetic interaction noted with concomitant administration of thrombolytic agents¹	If possible, discontinue other anticoagulants prior to initiating enoxaparin¹ If concomitant use is essential, careful clinical and laboratory monitoring advised¹

NSAIAs (e.g., ketorolac tromethamine)	Increased risk of bleeding¹	If possible, discontinue NSAIAs prior to initiating enoxaparin¹ If concomitant use is essential, careful clinical and laboratory monitoring advised¹
Dipyridamole	Increased risk of bleeding¹	If possible, discontinue dipyridamole prior to initiating enoxaparin¹ If concomitant use is essential, careful clinical and laboratory monitoring advised¹
Platelet inhibitors (e.g., aspirin, clopidogrel)	Increased risk of bleeding¹	If possible, discontinue platelet inhibitor prior to initiating enoxaparin; if concomitant use is essential, careful clinical and laboratory monitoring advised¹
Salicylates	Increased risk of bleeding¹	If possible, discontinue salicylates prior to initiating enoxaparin¹ If concomitant use is essential, careful clinical and laboratory monitoring advised¹
Sulfinpyrazone	Increased risk of bleeding¹	If possible, discontinue sulfinpyrazone prior to initiating enoxaparin¹ If concomitant use is essential, careful clinical and laboratory monitoring advised¹

Enoxaparin Pharmacokinetics

Absorption

Bioavailability

Mean absolute bioavailability of approximately 100% (based on anti-factor Xa activity) when given sub-Q in healthy individuals.¹

Onset

Maximum anti-factor Xa and antithrombin (anti-factor II_a) activities occur 3–5 hours after administration.¹

Direct IV injection of 30 mg immediately followed by 1 mg/kg dose sub-Q resulted in postinjection aPTT of 50 seconds.¹

Duration

Substantial anti-factor Xa activity persists in plasma for about 12 hours following administration (40 mg once daily).¹

Average aPTT prolongation on day 1 about 16% higher than on day 4.¹

Distribution

Extent

About 4.3 L (based on anti-factor Xa activity).¹

Enoxaparin does not appear to cross the placenta; not known whether the drug is distributed into milk.¹

Elimination

Metabolism

Metabolized, principally in the liver via desulfation and/or depolymerization, to less active metabolites.¹

Elimination Route

40% of dose is excreted in urine.¹

Half-life

4.5 hours after single sub-Q dose, approximately 7 hours after multiple dosing (based on anti-factor Xa activity).¹

Special Populations

Clearance reduced in patients with renal impairment.¹ In patients with severe renal impairment (Cl_cr <30 mL/minute), anti-factor Xa exposure (represented by AUC) was increased by approximately 65%.¹

Possible delayed elimination and increased exposure in geriatric patients.¹ ³

Stability

Storage

Parenteral

Solution for Injection

25°C (may be exposed to 15–30°C).¹

Do not store multiple-dose vials for >28 days after first use.¹

Compatibility

Parenteral

Solution Compatibility1

Compatible
Dextrose 5% in water
Sodium chloride 0.9%

Actions

An LMWH with antithrombotic properties.¹ ² ³ ⁴
Has less effect than unfractionated heparin on thrombin at a given level of anti-factor Xa activity.¹ ²
Prolongs some global clotting function tests (i.e., thrombin time, aPTT) by up to 1.8 times the control value.¹ At a sub-Q dosage of 1 mg/kg every 12 hours in a large clinical trial, aPTT was ≤45 seconds in most treated patients.¹

Advice to Patients

Importance of advising patients who have had neuraxial anesthesia or spinal puncture to monitor for manifestations of spinal or epidural hematoma (e.g., tingling or numbness in lower limbs, muscle weakness), particularly if they are receiving concomitant NSAIAs, platelet-aggregation inhibitors (e.g., clopidogrel), or other anticoagulants; importance of immediately contacting a clinician if any of these symptoms occur.¹
If therapy is to continue after hospital discharge, importance of instructing patient on proper injection technique of enoxaparin.¹
Importance of informing patients that they may bruise and/or bleed more easily and that a longer than normal time may be required to stop bleeding when taking enoxaparin.¹ Importance of patients reporting any unusual bleeding, bruising, or signs of thrombocytopenia (e.g., dark red spots under skin) to clinician.¹
Importance of patients informing clinicians (including dentists) that they are receiving enoxaparin therapy before scheduling any invasive procedures.¹
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.¹
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹
Importance of informing patients of other important precautionary information.¹ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Enoxaparin Sodium (Porcine)
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Parenteral	Injection, for subcutaneous and IV use	100 mg/mL*	Enoxaparin Sodium Injection
			Lovenox (available in single dose of 30, 40, 60, 80, or 100 mg as prefilled syringes or in a 3-mL multiple-dose vial)	Sanofi-Aventis
		150 mg/mL*	Enoxaparin Sodium Injection
			Lovenox (available in single dose of 120 or 150 mg as prefilled syringes)	Sanofi-Aventis

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Sanofi-Aventis US. Lovenox (enoxaparin sodium) injection prescribing information. Bridgewater, NJ; 2020 May.

2. Buckley MM, Sorkin EM. Enoxaparin: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs. 1992; 44:465-97. http://www.ncbi.nlm.nih.gov/pubmed/1382939?dopt=AbstractPlus

3. Turpie A. Enoxaparin prophylaxis in elective hip surgery. Acta Chir Scand Suppl. 1990; 556:103-107. http://www.ncbi.nlm.nih.gov/pubmed/1963014?dopt=AbstractPlus

4. Fareed J, Walenga JM, Lassen M et al. Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects. Acta Chir Scand Suppl. 1990; 556:75-90. http://www.ncbi.nlm.nih.gov/pubmed/1963021?dopt=AbstractPlus

5. Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl. 1990; 556:42-50. http://www.ncbi.nlm.nih.gov/pubmed/1705072?dopt=AbstractPlus

6. Planes A, Vochelle N, Fagola M et al. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep-vein thrombosis after total hip replacement. Acta Chir Scand Suppl. 1990; 556:108-15. http://www.ncbi.nlm.nih.gov/pubmed/1963015?dopt=AbstractPlus

7. Planes A, Vochelle N, Mazas F et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988; 60:407-10. http://www.ncbi.nlm.nih.gov/pubmed/2853459?dopt=AbstractPlus

8. Levine MN, Hirsh J, Gent M et al. Prevention of deep-vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991; 114:545- 51. http://www.ncbi.nlm.nih.gov/pubmed/1848054?dopt=AbstractPlus

9. Haas S, Flosbach CW. Prevention of post-operative thromboembolism in general surgery with enoxaparin: preliminary findings. Acta Chir Scand Suppl. 1990; 556:96-102. http://www.ncbi.nlm.nih.gov/pubmed/1963023?dopt=AbstractPlus

10. Spiro TE, Enoxaparin Clinical Trial Group. A randomized trial of enoxaparin administered post operatively for the prevention of deep-vein thrombosis following elective hip replacement surgery. Thromb Haemost. 1991; 65:927.

11. Griffiths MC, ed. USAN 1993: USAN and the USP dictionary of drug names. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1992:238-9.

12. Bara L, Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl. 1990; 556:57- 61. http://www.ncbi.nlm.nih.gov/pubmed/1963018?dopt=AbstractPlus

13. Fareed J, Walenga JM, Hoppensteadt D et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci. 1989; 556:333-53. http://www.ncbi.nlm.nih.gov/pubmed/2544128?dopt=AbstractPlus

14. Hoppensteadt D, Racanelli A, Walenga JM et al. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin. Semin Thromb Hemost. 1989; 15:378-85. http://www.ncbi.nlm.nih.gov/pubmed/2530633?dopt=AbstractPlus

15. Fareed J, Walenga JM, Hoppensteadt D et al. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemost. 1989; 15:440-63. http://www.ncbi.nlm.nih.gov/pubmed/2554505?dopt=AbstractPlus

16. Fareed J, Walenga JM, Williamson K et al. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost. 1985; 11:56-74. http://www.ncbi.nlm.nih.gov/pubmed/3883500?dopt=AbstractPlus

18. Spiro TE, Colwell CW, Trowbridge AA for the Enoxaparin Clinical Trial Group. A clinical trial comparing the efficacy and safety of enoxaparin, a low molecular weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement surgery.

19. Imperiale TF, Speroff T. A meta-anlysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994; 271:1780-5. http://www.ncbi.nlm.nih.gov/pubmed/7515115?dopt=AbstractPlus

20. Ledere JR, Geerts WH, Desjardins L et al. Prevention of deep-vein thrombosis after major knee surgery—a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost. 1992; 67:417-23. http://www.ncbi.nlm.nih.gov/pubmed/1321509?dopt=AbstractPlus

21. Spiro TE, Colwell CW, Bona RD et al et al. Enoxaparin versus unfractionated heparin for prevention of venous thromboembolic disease after elective knee replacement surgery. Chest. 1994; 106(Suppl 2):48S.

22. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs. 1995; 49:388-410. http://www.ncbi.nlm.nih.gov/pubmed/7774513?dopt=AbstractPlus

24. Heit JA, Berkowitz SD, Bona R et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost. 1997; 77:32-8. http://www.ncbi.nlm.nih.gov/pubmed/9031445?dopt=AbstractPlus

25. Hull R, Raskob G, Pineo G et al. A comparison of subcutaneous low-molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993; 329:1370-6. http://www.ncbi.nlm.nih.gov/pubmed/8413432?dopt=AbstractPlus

26. Lumpkin MM. Dear health care professional letter regarding reports of epidural or spinal hematomas with concurrent use of low molecular weight heparins or heparinoids and spinal/epidural anesthesia or spinal puncture. Rockville, MD: US Food and Drug Administration; 1997 Dec 15.

27. ENOXACAN Study Group. Efficacy of enoxaparin versus unfractionated heparin for prevention of deep-vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997; 84:1099-103. http://www.ncbi.nlm.nih.gov/pubmed/9278651?dopt=AbstractPlus

28. Dolovich LR, Ginsberg JS, Douketis JD et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med. 2000; 160:181-8. http://www.ncbi.nlm.nih.gov/pubmed/10647756?dopt=AbstractPlus

29. Levine M, Gent M, Hirsch J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996; 334:677-81. http://www.ncbi.nlm.nih.gov/pubmed/8594425?dopt=AbstractPlus

33. Francis CW, Pelligrini VD, Totterman S et al. Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. J Bone Joint Surg Am. 1997; 79:1365-72. http://www.ncbi.nlm.nih.gov/pubmed/9314399?dopt=AbstractPlus

34. Spiro TE, Johnson GJ, Christie MJ et al. Efficacy and safety of enoxaparin to prevent deep-vein thrombosis after hip replacement therapy. Ann Intern Med. 1994; 121:81-9. http://www.ncbi.nlm.nih.gov/pubmed/8017740?dopt=AbstractPlus

35. Planes A, Vochelle N, Darmon JY et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement: a prospective randomised double-blind placebo-controlled trial. Drugs. 1996; 52(Suppl 7):47-54. http://www.ncbi.nlm.nih.gov/pubmed/9042560?dopt=AbstractPlus

36. Bergqvist D, Benoni G, Bjorgell O et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335:696-700. http://www.ncbi.nlm.nih.gov/pubmed/8703168?dopt=AbstractPlus

37. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for reginal anesthetic management. Anesth Analg. 1997; 85:874-85. http://www.ncbi.nlm.nih.gov/pubmed/9322474?dopt=AbstractPlus

38. Davidson BL. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the Swedish study. Chest. 1998; 114(Suppl 2): 130S-2S.

40. Eikelboom JW, Anand SA, Malmberg K et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000; 355:1936-42. http://www.ncbi.nlm.nih.gov/pubmed/10859038?dopt=AbstractPlus

41. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997; 337:447-52. http://www.ncbi.nlm.nih.gov/pubmed/9250846?dopt=AbstractPlus

42. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999; 100:1593-601. http://www.ncbi.nlm.nih.gov/pubmed/10517729?dopt=AbstractPlus

43. Antman EM, Cohen M, Radley D et al. Asessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation. 1999; 100:1602-8. http://www.ncbi.nlm.nih.gov/pubmed/10517730?dopt=AbstractPlus

44. Armstrong PW. Pursuing progress in acute coronary syndromes. Circulation. 1999; 100:1586-9. http://www.ncbi.nlm.nih.gov/pubmed/10517727?dopt=AbstractPlus

45. Hull RD, Pineo GF, Francis C et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthoplasty patients: a double-blind, randomized comparison. Arch Intern Med. 2000; 160:2199-207. http://www.ncbi.nlm.nih.gov/pubmed/10904464?dopt=AbstractPlus

46. Eriksson BI, Kalebo P, Anthymyr BA et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparions of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 1991; 73:484-93. http://www.ncbi.nlm.nih.gov/pubmed/2013587?dopt=AbstractPlus

48. Antman EM, Fox KM for the International Cardiology Forum. Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. Am Heart J; 2000;139:461-75.

49. Wallentin L. New trials of LMW heparins-light and heavy weight as good on short but what about longer distances? Eur Heart J. 1999; 20:1522-24.

50. Agency for Health Care Policy and Research. Diagnosing and managing unstable angina. 1994. (AHCPR publication no. 94-0603)

51. Cairns JA, Theroux P, Lewis D et al. Antithrombotic agents in coronary artery disease. Chest. 1998; 114(Suppl 5):611S-33S. http://www.ncbi.nlm.nih.gov/pubmed/9822067?dopt=AbstractPlus

52. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol. 2000; 35:1699-702.

53. Klein W, Buchwald A, Hillis SE et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRISC). Circulation. 1997; 96:61-8. http://www.ncbi.nlm.nih.gov/pubmed/9236418?dopt=AbstractPlus

54. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996; 347:561-8. http://www.ncbi.nlm.nih.gov/pubmed/8596317?dopt=AbstractPlus

55. LeClerc JR, Geerts WH, Desjardins L et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med. 1996; 124:619-26. http://www.ncbi.nlm.nih.gov/pubmed/8607589?dopt=AbstractPlus

56. RD Heparin Arthroplasty Group. RD Heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am. 1994; 76:1174-85. http://www.ncbi.nlm.nih.gov/pubmed/8056798?dopt=AbstractPlus

58. Gould MK, Dembitzer AD, Doyle RL et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep-vein thombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1999; 130:800-9. http://www.ncbi.nlm.nih.gov/pubmed/10366369?dopt=AbstractPlus

64. Bonow RO, Carabello B, de Leon AC et al. ACC/AHA guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol. 1998; 32:1486-588. http://www.ncbi.nlm.nih.gov/pubmed/9809971?dopt=AbstractPlus

66. Mcleod RS,, Geerts WH, Sniderman KW et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery. Results of the Canadian colorectal DVT prophylaxis trials: a randomized, double-blind trial. Ann Surg. 2001; 233: 438-44. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1421263&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/11224634?dopt=AbstractPlus

67. Samama MM,, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999; 341: 793-800. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4280563&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/10477777?dopt=AbstractPlus

68. Kramer A, Gurevitch J et al. Low-molecular weight heparin for prosthetic heart valves: treatment failure. Ann Thorac Surg. 2000; 69:264-6. http://www.ncbi.nlm.nih.gov/pubmed/10654529?dopt=AbstractPlus

69. Rowan JA,, McCowan LM, Raudkivi PJ et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol. 2001; 185:633-7. http://www.ncbi.nlm.nih.gov/pubmed/11568791?dopt=AbstractPlus

70. Oles D,, Berryessa R, Campbell K et al. Emergency redo mitral valve replacement in a 27-year-old pregnant female with a clotted prosthetic mitral valve, preoperative fetal demise and postoperative ventricular assist device: a case report. Perfusion. 2001; 16:159-64. http://www.ncbi.nlm.nih.gov/pubmed/11334200?dopt=AbstractPlus

71. Sanofi-Aventis US. Personal communication

72. Cohen M, Bigonzi F et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one year results of the ESSENCE study. Efficacy and safety of subcutaneous enoxaparin in non-Q wave events. J Am Coll Cardiol. 2000; 36:693-8. http://www.ncbi.nlm.nih.gov/pubmed/10987586?dopt=AbstractPlus

76. Yeghiazarians Y, Braunstein JB, Askari A. Unstable angina pectoris. N Engl J Med. 2000; 342:101-14. http://www.ncbi.nlm.nih.gov/pubmed/10631280?dopt=AbstractPlus

77. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502. http://www.ncbi.nlm.nih.gov/pubmed/11519503?dopt=AbstractPlus

78. Ridker P, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med [serial online]. 2003; 348. Accessed February 24, 2003. http://content.nejm.org/cgi/content/abstract/NEJMoa035029v1

79. Schafer AI. Warfarin for venous thromboembolism—walking the dosing tightrope. N Engl J Med [serial online]. 2003; 348. Editorial. Accessed February 24, 2003. http://content.nejm.org/cgi/content/abstract/NEJMe030018v1

80. Anon. Benzyl alcohol may be toxic to newborns. FDA Drug Bull. 1982; 12:10-1.

81. American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983; 72:356-8. (IDIS 175725) http://www.ncbi.nlm.nih.gov/pubmed/6889041?dopt=AbstractPlus

82. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of lovenox in pregnancy. Obstet Gynecol. 2002;100:845-6.

83. Ginsberg JS, Chan WS, Bates SM et al. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med. 2003; 163:694-8. http://www.ncbi.nlm.nih.gov/pubmed/12639202?dopt=AbstractPlus

84. Vitale N, De Feo M, Cotrufo M. Anticoagulation for prosthetic heart valves during pregnancy: the importance of warfarin daily dose. Eur J Cardiothorac Surg. 2002; 22:656-7. Letter http://www.ncbi.nlm.nih.gov/pubmed/12297198?dopt=AbstractPlus

85. Leyh RT, Fischer S, Ruhparwar A et al. Anticoagulant therapy in pregnant women with mechanical heart valves. Arch Gynecol Obstet. 2003; 268:1-4 http://www.ncbi.nlm.nih.gov/pubmed/12673466?dopt=AbstractPlus

86. Srivastava AK, Gupta AK, Singh AV et al. Effect of oral anticoagulant during pregnancy with prosthetic heart valve. Asian Cardiovasc Thorac Ann. 2002; 10:306-9 http://www.ncbi.nlm.nih.gov/pubmed/12538273?dopt=AbstractPlus

87. Mahesh B, Evans S, Bryan AJ. Failure of low molecular-weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and a review of options for anticoagulation. J Heart Valve Dis. 2002; 11:745-50 http://www.ncbi.nlm.nih.gov/pubmed/12358414?dopt=AbstractPlus

88. Leyh RG, Fischer S, Ruhparwar A et al. Anticoagulation for prosthetic heart valves during pregnancy: is low-molecular-weight heparin an alternative? Eur J Cardiothorac Surg. 2002; 21:577-9

89. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000; 160:191-6 http://www.ncbi.nlm.nih.gov/pubmed/10647757?dopt=AbstractPlus

90. Berndt N, Khan I, Gallo R. A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report. J Heart Valve Dis. 2000; 9:844-6 http://www.ncbi.nlm.nih.gov/pubmed/11128796?dopt=AbstractPlus

91. Elkayam U. Pregnancy through a prosthetic heart valve. J Am Coll Cardiol. 1999; 33:1642-5. Editorial http://www.ncbi.nlm.nih.gov/pubmed/10334436?dopt=AbstractPlus

92. Meschengieser SS, Fondevila CG, Santarelli MT et al. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart. 1999; 82:23-6 http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1729094&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/10377303?dopt=AbstractPlus

93. Rowan JA, McCowan LM, Raudkivi PJ et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol. 2001; 185:633-7 http://www.ncbi.nlm.nih.gov/pubmed/11568791?dopt=AbstractPlus

94. Elkayam UR. Anticoagulation in pregnant women with prosthetic heart valves: a double jeopardy. J Am Coll Cardiol. 1996; 27:1704-6. Editorial http://www.ncbi.nlm.nih.gov/pubmed/8636557?dopt=AbstractPlus

95. Salazar E, Izaguirre R, Verdejo J et al. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol. 1996; 27:1698-703 http://www.ncbi.nlm.nih.gov/pubmed/8636556?dopt=AbstractPlus

96. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol. 1997; 176:1062-8

97. Schneider DM, Von Tempelhoff G-F, Heilmann L. Retrospective evaluation of the safety and efficacy of low-molecular-weight heparin as thromboprophylaxis during pregnancy. Am J Obstet Gynecol 1997; 177:1567-8. Letter http://www.ncbi.nlm.nih.gov/pubmed/9423786?dopt=AbstractPlus

98. Arnaout MS, Kazma H, Khalil A et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? Clin Exp Obstet Gynecol. 1998; 25:101-4

99. Vitale N, De Feo M, De Santo LS et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999; 33:1637-41 http://www.ncbi.nlm.nih.gov/pubmed/10334435?dopt=AbstractPlus

101. American College of Obstetricians and Gynecologists, Washington, DC. Personal communication.

109. Adams H, Adams R, Del Zoppo G et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update. A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke. 2005; 36:916-21. http://www.ncbi.nlm.nih.gov/pubmed/15800252?dopt=AbstractPlus

110. Adams H, Adams R, Brott T et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003; 34:1056-83. http://www.ncbi.nlm.nih.gov/pubmed/12677087?dopt=AbstractPlus

115. Fox KA, Poole-Wilson PA, Henderson RA. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet. 2002; 360:743-51. http://www.ncbi.nlm.nih.gov/pubmed/12241831?dopt=AbstractPlus

116. Husted SE, Wallentin L, Lagerqvist B et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J. 2002; 23:1213-8. http://www.ncbi.nlm.nih.gov/pubmed/12127923?dopt=AbstractPlus

117. Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-segment-elevation acute coronary syndrome: insights for the INTERACT trial. Am Heart J. 2005; 149:S73-80. http://www.ncbi.nlm.nih.gov/pubmed/16124951?dopt=AbstractPlus

119. James S, amrstrong P, Califf R et al. Safety and efficacy of abciximab combined with dalteparin in the treatment of acute coronary syndromes. Eur Heart J. 2002; 23:1538-45. http://www.ncbi.nlm.nih.gov/pubmed/12242074?dopt=AbstractPlus

120. Goodman SG, Fitchett D, Armstrong P et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfarctionated heparin in high-risk patients with non-ST-sgement elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003; 107:238-44. http://www.ncbi.nlm.nih.gov/pubmed/12538422?dopt=AbstractPlus

121. Collet JP, Montalescot G, Golmard JL et al. Subcutaneous enoxaparin with early invasive stragety in patients with acute coronary syndromes. Am Heart J. 2004; 147:655-61. http://www.ncbi.nlm.nih.gov/pubmed/15077081?dopt=AbstractPlus

122. Eikelboom JW, Hankey GJ. Low molecular weight heparins and heparinoids. Med J Aust. 2002; 177:379-83. http://www.ncbi.nlm.nih.gov/pubmed/12358583?dopt=AbstractPlus

124. Bhatt DL, Roe MT, Peterson ED et al. Utilization of early invasive management strategies for high-risk patients with non–ST-segment elevation acute coronary syndromes. Results from the CRUSADE Quality Improvement Initiative. JAMA. 2004; 292:2096-2104. http://www.ncbi.nlm.nih.gov/pubmed/15523070?dopt=AbstractPlus

125. Gluckman TJ, Sachdev M, Schulman SP et al. A simplified approach to the management of non–ST-segment elevation acute coronary syndromes. JAMA. 2005; 293:349-357. http://www.ncbi.nlm.nih.gov/pubmed/15657328?dopt=AbstractPlus

126. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001; 344:1879–87. http://www.ncbi.nlm.nih.gov/pubmed/11419424?dopt=AbstractPlus

127. Braunwald E. Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. Circulation. 2003; 108[Suppl III]:III-28-37.

128. Hirsh J, Bauer KA, Donati MB et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133:141S-159S. http://www.ncbi.nlm.nih.gov/pubmed/18574264?dopt=AbstractPlus

129. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001; 358:605-13. http://www.ncbi.nlm.nih.gov/pubmed/11530146?dopt=AbstractPlus

130. Wallentin L, Goldstein P, Armstrong PW et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003; 108:135-42. http://www.ncbi.nlm.nih.gov/pubmed/12847070?dopt=AbstractPlus

131. Ross AM, Molhoek P, Lundergan C et al et al. Randomized comparison of enoxaparin, a lowmolecular- weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. 2001; 104:648-52. http://www.ncbi.nlm.nih.gov/pubmed/11489769?dopt=AbstractPlus

132. Wallentin L, Bergstrand L, Dellborg M et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J. 2003; 24:897-908. http://www.ncbi.nlm.nih.gov/pubmed/12714021?dopt=AbstractPlus

133. Baird SH, Menown IB, Mcbride SJ et al. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J. 2002; 23:627-32. http://www.ncbi.nlm.nih.gov/pubmed/11969277?dopt=AbstractPlus

135. Lansky AJ, Hochman JS, Ward PA et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professional from the American Heart Association. Circulation. 2005; 111:940-3. http://www.ncbi.nlm.nih.gov/pubmed/15687113?dopt=AbstractPlus

136. Mahaffey KW, Ferguson JJ, Califf RM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004; 292:45-54. http://www.ncbi.nlm.nih.gov/pubmed/15238590?dopt=AbstractPlus

138. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45:2160-236. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus

142. Wysowski DK, Talarico L, Bacsanyi J et al. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med. 1998; 338:1774. http://www.ncbi.nlm.nih.gov/pubmed/9625640?dopt=AbstractPlus

143. Weitz JI. Low molecular weight heparins. N Engl J Med. 1998; 338:687-8. http://www.ncbi.nlm.nih.gov/pubmed/9490390?dopt=AbstractPlus

146. Wallentin L, Lagerqvist B, Husted S et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet. 2000; 356:9-16. http://www.ncbi.nlm.nih.gov/pubmed/10892758?dopt=AbstractPlus

150. Sanofi-Aventis. Lovenox (enoxaparin sodium) injection prescribing information. Bridgewater, NJ; 2011 Apr.

161. US Food and Drug Administration. FDA drug safety communications: Updated recommendations to decrease risk of spinal column bleeding and paralysis in patients on low molecular weight heparins. 2013 Nov 6. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm373595.htm

162. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006; 354:1477-88. http://www.ncbi.nlm.nih.gov/pubmed/16537665?dopt=AbstractPlus

163. Horlocker TT, Wedel DJ, Rowlingson JC et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010 Jan-Feb; 35:64-101.

164. Gibbons RJ, Fuster V. Therapy for patients with acute coronary syndromes—new opportunities. N Engl J Med. 2006; 354:1524-7. Editorial. http://www.ncbi.nlm.nih.gov/pubmed/16537664?dopt=AbstractPlus

165. Morrow DA, Antman EM, Fox KAA et al. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 Trial. Eur Heart J. 2010; 31:2097–2102.

166. Sanofi-Aventis, Bridgewater, NJ: Personal communication.

167. Gibson CM, Murphy SA, Montalescot G et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007; 49:2238-46. http://www.ncbi.nlm.nih.gov/pubmed/17560287?dopt=AbstractPlus

168. Boehringer Ingelheim Pharmaceutical. Pradaxa (dabigatran mesylate) capsule prescribing information. Ridgefield, CT; 2021 Apr.

169. Daiichi Sankyo Inc. Savaysa (edoxaban tosylate) film coated tablet prescribing information. Basking Ridge, NJ; 2021 Mar.

170. Bristol-Myers Squibb Company and Pfizer Inc. Eliquis (apixaban) film coated tablet prescribing information. Princeton NJ and New York, NY; 2021 Apr.

171. Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) film coated tablet prescribing information. Titusville, NJ; 2021 Feb.

172. Kahale LA, Hakoum MB, Tsolakian IG et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018; 6:CD006650. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC6389342&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/29920657?dopt=AbstractPlus

173. Liu X, Johnson M, Mardekian J et al. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. J Am Heart Assoc. 2015; 4 http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC4845271&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/26627879?dopt=AbstractPlus

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3695607&blobtype=pdf

805. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017; 389:197-210. http://www.ncbi.nlm.nih.gov/pubmed/27502078?dopt=AbstractPlus

991. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e344-426. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4676081&blobtype=pdf

994. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58:e44-122. http://www.ncbi.nlm.nih.gov/pubmed/22070834?dopt=AbstractPlus

996. Otto CM, Nishimura RA, Bonow RO et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143:e72-e227. http://www.ncbi.nlm.nih.gov/pubmed/33332150?dopt=AbstractPlus

999. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64:e1-76. http://www.ncbi.nlm.nih.gov/pubmed/24685669?dopt=AbstractPlus

1000. Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e152S-84S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278055&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315259?dopt=AbstractPlus

1001. Kahn SR, Lim W, Dunn AS et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e195S-226S.

1002. Gould MK, Garcia DA, Wren SM et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e227S-77S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278061&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315263?dopt=AbstractPlus

1003. Falck-Ytter Y, Francis CW, Johanson NA et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e278S-325S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278063&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315265?dopt=AbstractPlus

1004. Douketis JD, Spyropoulos AC, Spencer FA et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e326S-50S.

1005. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-94S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278049&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315268?dopt=AbstractPlus

1006. Linkins LA, Dans AL, Moores LK et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e495S-530S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278058&blobtype=pdf

1007. Lip GYH, Banerjee A, Boriani G et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018; 154:1121-1201. http://www.ncbi.nlm.nih.gov/pubmed/30144419?dopt=AbstractPlus

1008. Whitlock RP, Sun JC, Fremes SE et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e576S-600S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278057&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315272?dopt=AbstractPlus

1009. Lansberg MG, O'Donnell MJ, Khatri P et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e601S-36S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278065&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315273?dopt=AbstractPlus

1010. Garcia DA, Baglin TP, Weitz JI et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:e24S-e43S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC3278070&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315264?dopt=AbstractPlus

1012. Bates SM, Greer IA, Middeldorp S et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e691S-736S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278054&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315276?dopt=AbstractPlus

1013. Monagle P, Chan AK, Goldenberg NA et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e737S-801S. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3278066&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22315277?dopt=AbstractPlus

1014. Douketis JD, Spyropoulos AC, Kaatz S et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015; 373:823-33. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC4931686&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/26095867?dopt=AbstractPlus

1017. Bushnell C, McCullough LD, Awad IA et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45:1545-88. http://www.ncbi.nlm.nih.gov/pubmed/24503673?dopt=AbstractPlus

1101. Anderson DR, Morgano GP, Bennett C et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019; 3:3898-3944. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC6963238&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/31794602?dopt=AbstractPlus

1102. Key NS, Khorana AA, Kuderer NM et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020; 38:496-520. http://www.ncbi.nlm.nih.gov/pubmed/31381464?dopt=AbstractPlus

1103. . Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. Blood Adv. 2021; 5:1953. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC8045511&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/33821993?dopt=AbstractPlus

1104. Kearon C, Akl EA, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149:315-352. http://www.ncbi.nlm.nih.gov/pubmed/26867832?dopt=AbstractPlus

1105. Writing Group Members., January CT, Wann LS et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2019; 16:e66-e93. http://www.ncbi.nlm.nih.gov/pubmed/30703530?dopt=AbstractPlus

1106. Witt DM, Nieuwlaat R, Clark NP et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018; 2:3257-3291. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC6258922&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/30482765?dopt=AbstractPlus

1107. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics.. ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet Gynecol. 2018; 132:e1-e17. http://www.ncbi.nlm.nih.gov/pubmed/29939938?dopt=AbstractPlus

1108. Schünemann HJ, Cushman M, Burnett AE et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018; 2:3198-3225. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC6258910&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/30482763?dopt=AbstractPlus

1109. Barkoudah E, Piazza G, Hecht TEH et al. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. Am J Med. 2020; 133 Suppl 1:1-27. http://www.ncbi.nlm.nih.gov/pubmed/32362349?dopt=AbstractPlus

More about enoxaparin

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

6.8 / 10

26 Reviews